Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

MLN 944

Known as: MLN-944, MLN944 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Structure activity relationships for tricyclic‐carboxamide topoisomerase II poisons indicate that cytotoxicity is enhanced by the… Expand
2014
2014
MLN 944 is a bisintercalating DNA‐binding antitumor agent known to be a template inhibitor of transcription. Previous 1H NMR… Expand
2005
2005
XR5944 (MLN944), a novel bis-phenazine, has demonstrated potent cytotoxic activity against a variety of murine and human tumour… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
2005
2005
MLN944 is a novel compound currently being codeveloped by Millennium Pharmaceuticals and Xenova Ltd. as a cancer therapeutic and… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2005
2005
XR5944 (MLN944) is a novel bis-phenazine currently in phase I clinical trials that has demonstrated potent cytotoxic activity… Expand
Highly Cited
2004
Highly Cited
2004
The new bisphenazine anticancer drug MLN944 is a novel cytotoxic agent with exceptional anti-tumor activity against a range of… Expand
  • figure 1
  • table I
  • figure 2
  • figure 3
  • table II
2004
2004
MLN944 (XR5944) is a novel bis-phenazine that has demonstrated exceptional efficacy against a number of murine and human tumor… Expand
2004
2004
XR5944 (MLN944) is a novel DNA targeting agent with potent antitumor activity, both in vitro and in vivo, against several murine… Expand
2004
2004
2100 Background: XR5994 (MLN944) is a novel DNA/RNA targeting agent with a mechanism of action distinct from that of currently… Expand